A rare drug-resistant strain of Klebsiella pneumoniae in Houston, Texas, was found

A rare drug-resistant strain of Klebsiella pneumoniae in Houston,
Texas, was found
Recently, the deadly "superbug" Klebsiella pneumoniae is out of trouble?
The Houston Methodist Institute led the genetic testing of 2000 Klebsiella
pneumoniae strains in local hospital patients. Klebsiella pneumoniae is the most
important type of bacteria in the genus Enterobacter, which causes more than 95% of
Klebsiella infections.
Klebsiella pneumoniae is one of the main pathogens of clinical isolation and
nosocomial infection. At the same time, Klebsiella, Pseudomonas aeruginosa and
Serratia were all important pathogens in nosocomial septicemia, and the fatality rate
was higher than that of Klebsiella aeruginosa and Serratia.
As reported in mBio, researchers have found that a rare clone group is more
susceptible to infection than a strain in nature, like a highly toxic strain.
James Musser, a leading author of Houston Methodist Hospital, said in a
statement: "it is very surprising to find a rare strain in our city. Klebsiella pneumoniae
is a common and important cause of human infection. We urgently need to identify
potential vaccine targets or other new treatments, and to develop new, rapid
diagnostic techniques. "
Chlamydia pneumoniae lives in the human gut and does not cause any trouble.
However, bacteria can cause severe infections in other parts of the body and outside
the body. Inpatients are at particularly high risk for severe bacterial infections, the
researchers explained.
The bacteria can cause harmful infections, such as pneumonia, blood flu and
meningitis, once it moves out of the intestine and into other body parts.
This is not the first time this year for Mycoplasma pneumoniae to be released in
the United States. Earlier this year, an elderly Nevada woman died of the bacteria.
The researchers say it resists all 26 antibiotics used in the United States.
The researchers found super endurance's final antibiotic height: PlayVideoCBS.
Musser and his colleagues examined the bacterial genome of 1777 Klebsiella
pneumoniae strains from extended beta-lactamase (ESBL) collected from the Houston
Methodist Hospital patient system between 2011 and 2015. They developed
evolutionary trees of Klebsiella pneumoniae producing ESBL.
In other countries or places, a large number of hospitals carried out a study of
Klebsiella pneumoniae and found that CG258 had a leading role in the tree. The
Houston researchers mentioned in the report that CG258 accounted for only 1/4 of the
number of samples. On the contrary, they found that more than 1/3 of the strain in the

sample belonged to the CG307 evolution branch and the remaining strains were
heterogeneous.
Researchers pay that none of the hospitals in the system are infected with CG307
or CG258. However, throughout the study, it can be found that CG307 and CG258 are
common in the population. However, it is not clear why CG307 is so common in
Houston.
The researchers further carried out the CG307&CG258 mice experiment. Mice
infected with CG307/CG258 showed no difference in bacterial load between the two
groups. Although CG307 branches lead to low levels of IL-17, both bacteria trigger
an immune response in mice. However, this and other clinical trials have shown that
CG207 is as toxic as CG208.
Musser and his colleagues used Pacific Biosciences's long-reading sequencing
platform for bacterial RNA sequencing on five strains from their samples. They
reported that the strains contained 5 plasmids, usually containing antibiotic resistance
genes.
In particular, the researchers found that in the cohort, 64.6% of CG258 strains
and 34.3% of CG307 strains were CGPC alleles (which give carbapenase resistance).
In some strains, they also revealed the gene encoding metallo-β-lactamase 1 (NDM-1)
in New Delhi. And the plasmid can be easily transferred.
The RNA sequencing of the patient subgroup further revealed that the strains
carrying KPC,NDM-1,OXA-48 and Yersinia resistance genes did express them.
Using a machine-learning approach, Musser and his colleagues developed a
classifier that uses bacterial genome-wide sequences to predict antibiotic resistance.
They report that the results of their AdaBoost-based algorithms are closely related to
clinical phenotypes.
Wesley Long, lead author of Houston Methodist Hospital, said: "the combination
of complex and novel computing and molecular strategies allows us to quickly
identify drug-resistant strains. "We can identify antibiotics that are sensitive to this
strain more quickly, and the faster the therapists can treat these patients, the more
quickly it is possible for them to be properly treated.